Part I Technology and Probe Design

Computed Tomography and Magnetic Resonance Imaging ............ 3
1 Imaging Targets in Cancer ............................................. 4
  1.1 Introduction ....................................................... 4
  1.2 Physiological Imaging Targets ................................. 5
  1.3 Molecular Targets ................................................. 7
  1.4 Cellular Targets ................................................... 8
  1.5 Image-Guided Drug Delivery .................................... 8
2 Recent Technological Developments in X-ray Computed
  Tomography of Cancer ................................................... 9
  2.1 Basics of Multi-Slice Spiral Computed Tomography .......... 9
  2.2 Multi-Energy Computed Tomography ............................ 13
  2.3 Preclinical Computed Tomography ............................... 14
  2.4 Dedicated Imaging Systems and New Developments .......... 15
  2.5 Multimodality Imaging ............................................ 16
3 Recent Technological Developments in Magnetic Resonance
  Imaging of Cancer ....................................................... 16
  3.1 Magnetic Resonance Imaging: Introduction .................... 16
  3.2 MRI Signal Formation and Contrast ............................ 17
  3.3 Magnetic Field Strength and Signal Sensitivity ............... 21
  3.4 Imaging Gradients, Signal Encoding, and Signal
    Reception Chain .................................................... 21
  3.5 MRI Pulse Sequences, Parametric Mapping .................... 23
  3.6 Contrast-Enhanced MRI .......................................... 24
4 Imaging Biomarkers in Cancer ......................................... 25
  4.1 Imaging Biomarkers: X-ray Computed Tomography ............ 25
  4.2 Imaging Biomarkers: Magnetic Resonance Imaging ........... 26
5 Magnetic Resonance Imaging Probes in Cancer ........................ 33
  5.1 Introduction .......................................................... 33
  5.2 Non-Targeted Probes .............................................. 33
  5.3 Targeted Probes .................................................... 43
  5.4 Responsive Probes ................................................ 43
  5.5 Reporter Genes .................................................... 45
Single Photon Emission Computed Tomography Tracer

1 Introduction
2 General Aspects for the Design of SPECT Tracers
3 Peptide-Receptor Radionuclide Imaging
   3.1 Somatostatin Analogs
   3.2 Bombesin Analogs
   3.3 Neurotensin Analogs
   3.4 Other Peptides-Based Radiotracers
4 Antibodies and Antibody Fragments
   4.1 Targeting Fibronectin Extra-Domain B: Antiangiogenic Antibody Fragment L19
5 Vitamin-Based Radiotracers
   5.1 Folic Acid Conjugates
   5.2 Vitamin B12 Conjugates
   5.3 Other Vitamin Targeting Agents
6 Intracellular Targets
   6.1 99mTc-Carbohydrate Complexes
   6.2 Radiolabeled Nucleoside Analogs for Targeting Human Thymidine Kinase
   6.3 Radioiodinated Meta-Iodobenzylguanidine
7 Optimization of SPECT Tracer Design and Potential Reasons for Failure
8 Summary and Conclusion

Non-peptidyl 18F-Labelled PET Tracers as Radioindicators for the Noninvasive Detection of Cancer

1 Introduction
2 [18F]FDG for Imaging Glucose Metabolism
3 18F-Labelled Amino Acids (AAs) for Imaging AA Transport and Protein Synthesis
   3.1 O-(2-[18F]Fluoroethyl)-l-tyrosine ([18F]FET)
   3.2 6-[18F]Fluoro-3,4-dihydroxy-l-phenylalanine ([18F]FDOPA)
4 18F-Labelled Choline Derivatives for Imaging Membrane Lipid Synthesis
5 18F-Labelled Nucleoside Derivatives for Imaging Cell Proliferation
5.1 3′-Deoxy-3′-[18F]fluoro-l-thymidine ([18F]FLT) .......................... 118
5.2 1-(2′-Deoxy-2′-[18F]fluoro-β-d-arabinofuranosyl)-5-methyluracil ([18F]FMAU). .......................... 119
6 18F-Labelled Nitroimidazole Derivatives for Imaging
   Tumour Hypoxia ...................................................... 120
   6.1 [18F]Fluoromisonidazole ([18F]FMISO) ........................................ 120
   6.2 1-(5-Deoxy-5-[18F]Fluoro-α-d-arabinofuranosyl)-2-nitroimidazole ([18F]FAZA) ..................................... 122
7 [18F]FES for Imaging Estrogen Receptor Status .................................. 122
8 [18F]Fluoride for Imaging Bone Metabolism ...................................... 124
9 Perspectives .......................................................... 124
References ................................................................ 125

Optical and Opto-Acoustic Imaging .................................................. 133
1 Introduction ........................................................................ 134
2 Multi-Spectral Optoacoustic Tomography .................................... 135
   2.1 Sensitivity of Biomarker Detection .................................... 139
   2.2 Other Applications of Optoacoustic Imaging .................... 142
3 FMT-XCT ................................................................. 142
4 Overview of Performance Characteristics .................................... 145
5 Quantification .................................................................... 146
6 Optical Imaging Applications in Oncology ..................................... 148
References ................................................................ 149

Multifunctional Magnetic Resonance Imaging Probes .................... 151
1 The Need for Imaging and Contrast Agents in Oncology ............ 152
2 Imaging Techniques and Contrast Agents ................................ 155
   2.1 Magnetic Resonance Imaging of Cancer ......................... 155
   2.2 Multifunctional Imaging Probes .................................... 159
3 Probing the Tumor Vasculature ............................................... 161
   3.1 Dynamic Contrast-Enhanced MRI .................................. 162
   3.2 Macromolecular Dynamic Contrast-Enhanced MRI .......... 164
4 Molecular Imaging .................................................................. 167
5 Combined Imaging and Therapy .............................................. 175
6 Translations and Future Outlook .............................................. 181
References ................................................................ 183

Part II Preclinical Studies

Preclinical SPECT and SPECT/CT .................................................. 193
1 Introduction ........................................................................ 194
2 Part I: Considerations when Evaluating the Potential Role of SPECT/CT Imaging in a Preclinical Oncology Research Application ........................................ 195
  2.1 Choice and Implications of Various Small Animal Models of Cancer ........................................ 195
  2.2 Framing the Research Question in Imaging Terms ........................................ 198
  2.3 Available in vivo Imaging Modalities and Characteristics of Preclinical Oncology Applications Amenable to SPECT ........................................ 198
  2.4 SPECT Versus SPECT/CT ........................................ 199

3 Part II: Technical Considerations when Implementing SPECT/CT in Preclinical Oncology Research .................. 200
  3.1 Anesthesia and Animal Handling ........................................ 200
  3.2 Availability of Radiopharmaceuticals and Evaluation of Their Biodistribution Characteristics ........................................ 201
  3.3 Injection of the Radiopharmaceutical ........................................ 203
  3.4 Injection of CT Contrast Agent ........................................ 203
  3.5 Radiation Exposure ........................................ 203

4 Part III: State-of-the-Art Preclinical SPECT/CT Systems .................. 205
  4.1 SPECT/CT System Design ........................................ 205
  4.2 A Sampling of Available Small-Animal SPECT- and SPECT/CT Systems ........................................ 207
  4.3 Image Reconstruction Techniques and the Quest for Quantitative SPECT ........................................ 208

5 Part IV: Recent Examples of SPECT/CT as Applied in the Preclinical Oncology Setting .................. 210
  5.1 Characterizing Tumor Perfusion or Other Inherent Characteristics ........................................ 210
  5.2 Imaging the Targeting Abilities of Molecules in the Development of Potential Therapeutics and Molecular Imaging Agents ........................................ 210
  5.3 Imaging Cell Trafficking ........................................ 213
  5.4 Imaging Gene Transfer and Expression ........................................ 213
  5.5 Imaging Biodistributions and Evaluating Dosimetry—Chemotherapeutics and Combined Therapeutic/Imaging Agents ........................................ 215
  5.6 Imaging Other Pathologic Processes Associated with Cancer or Cancer Therapies ........................................ 216

6 Conclusion ........................................ 216

References ........................................ 216

Optical Imaging ........................................ 221
  1 Non-Invasive Optical Imaging Techniques ........................................ 222
  2 Imaging Agents for Fluorescence Imaging ........................................ 223
  3 Reporter Systems for Bioluminescence Imaging ........................................ 224
### Part III  Clinical Applications

#### Quantitative SPECT/CT  

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction</td>
<td>314</td>
</tr>
<tr>
<td>2</td>
<td>Technical Aspects</td>
<td>314</td>
</tr>
<tr>
<td>2.1</td>
<td>SPECT/CT Instrumentation</td>
<td>314</td>
</tr>
<tr>
<td>2.2</td>
<td>Registration of Multimodal Images</td>
<td>315</td>
</tr>
<tr>
<td>2.3</td>
<td>Attenuation Correction of SPECT</td>
<td>316</td>
</tr>
<tr>
<td>2.4</td>
<td>Quantitatively Accurate SPECT/CT</td>
<td>318</td>
</tr>
<tr>
<td>3</td>
<td>Clinical Aspects</td>
<td>326</td>
</tr>
<tr>
<td>4</td>
<td>Summary and Outlook</td>
<td>327</td>
</tr>
<tr>
<td>References</td>
<td></td>
<td>327</td>
</tr>
</tbody>
</table>

#### Optical Imaging of Breast Tumors and of Gastrointestinal Cancer by Laser-Induced Fluorescence  

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction</td>
<td>332</td>
</tr>
<tr>
<td>2</td>
<td>Fluorescence Imaging of Breast Cancer</td>
<td>333</td>
</tr>
<tr>
<td>2.1</td>
<td>The PTB Fluorescence Mammograph</td>
<td>334</td>
</tr>
<tr>
<td>2.2</td>
<td>Examination Protocol</td>
<td>336</td>
</tr>
<tr>
<td>2.3</td>
<td>Results on Malignant and Benign Tumors</td>
<td>337</td>
</tr>
<tr>
<td>2.4</td>
<td>Advances of Permeability Sensitive Fluorescence Imaging with ICG</td>
<td>340</td>
</tr>
<tr>
<td>3</td>
<td>Cancer and Early Malignancies of the GI</td>
<td>343</td>
</tr>
<tr>
<td>3.1</td>
<td>Protoporphyrin IX as Tumor Marker</td>
<td>343</td>
</tr>
<tr>
<td>3.2</td>
<td>Time-Gated Fluorescence Imaging</td>
<td>343</td>
</tr>
<tr>
<td>3.3</td>
<td>Clinical Studies</td>
<td>346</td>
</tr>
<tr>
<td>4</td>
<td>Outlook</td>
<td>347</td>
</tr>
<tr>
<td>References</td>
<td></td>
<td>348</td>
</tr>
</tbody>
</table>

#### FDG PET and PET/CT  

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Introduction</td>
<td>352</td>
</tr>
<tr>
<td>2</td>
<td>Clinical Applications of FDG PET and PET/CT in Oncology</td>
<td>353</td>
</tr>
<tr>
<td>2.1</td>
<td>Non-Small Cell Lung Cancer</td>
<td>353</td>
</tr>
<tr>
<td>2.2</td>
<td>Oesophageal Cancer</td>
<td>355</td>
</tr>
<tr>
<td>2.3</td>
<td>Gastric Cancer</td>
<td>355</td>
</tr>
<tr>
<td>2.4</td>
<td>Colorectal Cancer</td>
<td>356</td>
</tr>
<tr>
<td>2.5</td>
<td>Gastrointestinal Stromal Tumors</td>
<td>356</td>
</tr>
<tr>
<td>2.6</td>
<td>Head and Neck Cancer</td>
<td>357</td>
</tr>
<tr>
<td>2.7</td>
<td>Melanoma</td>
<td>357</td>
</tr>
<tr>
<td>2.8</td>
<td>Lymphoma</td>
<td>358</td>
</tr>
<tr>
<td>2.9</td>
<td>Breast Cancer</td>
<td>359</td>
</tr>
<tr>
<td>2.10</td>
<td>Ovarian Cancer</td>
<td>360</td>
</tr>
<tr>
<td>2.11</td>
<td>Sarcomas</td>
<td>361</td>
</tr>
<tr>
<td>2.12</td>
<td>Pancreatic Cancer</td>
<td>362</td>
</tr>
</tbody>
</table>
Molecular Imaging in Oncology
Schober, O.; Riemann, B. (Eds.)
2013, XVI, 416 p., Hardcover
ISBN: 978-3-642-10852-5